Sinusitis Tied to Later Autoimmune Disease
(MedPage Today) -- A history of sinus congestion and drip may be a precursor to serious autoimmune disorders, a population-based study suggested.
Rates of rheumatologic conditions including antiphospholipid syndrome and Sjögren's disease... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 28, 2024 Category: Infectious Diseases Source Type: news
Antiphospholipid Antibodies Vary by Race in People With SLE Antiphospholipid Antibodies Vary by Race in People With SLE
A study of multiple cohorts of patients with systemic lupus erythematosus showed significantly lower prevalence of antiphospholipid antibodies (aPLs) among Black patients.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 2, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Pregnancies With Sj ögren's Are Largely Safe Pregnancies With Sj ögren's Are Largely Safe
There was no difference in risk of adverse pregnancy outcomes between women with Sj ögren ' s and the control group, but negative outcomes were more frequent with antiphospholipid antibodies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2023 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Antiphospholipid Antibodies Linked to Future CV Events Antiphospholipid Antibodies Linked to Future CV Events
The study raises the possibility of one day treating the immune system in some individuals for the prevention and treatment of cardiovascular disease, researchers suggest.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 6, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Warfarin Best for Thrombotic Antiphospholipid Syndrome? Warfarin Best for Thrombotic Antiphospholipid Syndrome?
Patients with thrombotic antiphospholipid syndrome appear better treated with a vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, a new meta-analysis suggests.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 10, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
ACR, EULAR Roll Out Updated Antiphospholipid Syndrome Criteria ACR, EULAR Roll Out Updated Antiphospholipid Syndrome Criteria
A joint planning group proposes updates to 16-year-old criteria for classifying antiphospholipid syndrome.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2022 Category: Cancer & Oncology Tags: Rheumatology News Source Type: news
How Changing Your Diet Could Have a Major Impact on Managing Lupus Symptoms
After Jewell Singletary was diagnosed with lupus, she developed rheumatoid arthritis as well—a common pairing, since both are autoimmune conditions—and had to use a cane to navigate her college campus. When she graduated, the now 38-year-old New Jersey resident decided to be more focused on supporting her health, in an effort to maintain her mobility as she began her career.
She started in the kitchen.
First to be tossed were sugary drinks, fried foods, and highly processed options, she says. Once she eliminated them, it didn’t take long before she could discard one more important item: her cane.
[time-br...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Diet & Nutrition freelance healthscienceclimate Source Type: news
What are Potential Problems with Placental Abnormalities?
Discussion
“The placenta is a unique organ that sits at the interface of, and facilitates nearly all interactions between, maternal and fetal physiology. It is the sole source of oxygen and nutrition for the fetus, and provides a protective barrier against external insults. The placenta is also a highly adaptable organ that is capable of showing a wide range of pathological changes in response to various maternal and fetal factors and stressors.” The placenta has 3 layers: the amnion (fetal side), the chorion, and decidua (maternal side). In addition to making observations about the maternal and fetal sides, co...
Source: PediatricEducation.org - June 27, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Chilblains: An Old But Now More Common Problem
Discussion
Chilblains is also known as perniosis is an “…inflammatory dermatosis that generally affects the dorsal feet or hands during the periods of damp and cold, but not freezing, conditions…” It produces acryl lesions.
Chilblains may be derived from the Old English words “chill” and “blegen” (sore). Pernio is thought be derivative of pern(a) or haunch of the leg as the feet and legs are commonly affected. Chilblain is usually idiopathic but has been associated with Raynaud disease, blood problems including cryofibrinogenemia and rheumatologic conditions such as systemic ...
Source: PediatricEducation.org - May 30, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Novel Antibody Response Test May Aid in Lyme Disease Diagnostics, Detect Recurrence Novel Antibody Response Test May Aid in Lyme Disease Diagnostics, Detect Recurrence
A test that detects antiphospholipid antibodies in the blood of Lyme disease patients shows potential for identifying the disease sooner than current methods and possibly tracking response to therapy and recurrence, researchers say.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 5, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Antibody-Activated Endothelial Cells Increase the Risk of Blood Clots with Covid-19
Antiphospholipid antibodies activity may help explain hypercoagulation associated with late stages of Covid-19 and long-haul disease. Blood samples from nearly 250 individuals hospitalized for Covid-19 found that these “rouge” antibodies activate endothelial cells, risking widespread blood clots. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 4, 2022 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
